ARWR

20.57

2.54% 0.51

Dopo l'orario di chiusura: 20.11 -0.46 -2.24%

Arrowhead Pharmaceuticals Inc (ARWR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ARWR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$20.06

Aprire:

$20.025

Volume 24 ore:

778.15K

Relative Volume:

0.77

Capitalizzazione di mercato:

$2.55B

Reddito:

$181.74M

Utile/perdita netta:

$-296.81M

Rapporto P/E:

-12.03

EPS:

-1.71

Flusso di cassa netto:

$-402.70M

1 W Prestazione:

+2.95%

1M Prestazione:

+9.30%

6M Prestazione:

-15.83%

1 anno Prestazione:

-26.93%

Intervallo 1D:

$19.63

$20.59

Intervallo di 1 settimana:

$19.20

$20.59

Portata 52W:

$17.05

$39.83

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Nome

Arrowhead Pharmaceuticals Inc

Settore

Healthcare (1182)

Industria

Biotechnology (671)

Telefono

626-696-4702

Indirizzo

177 E COLORADO BLVD, PASADENA, CA

Dipendente

525

Cinguettio

@ArrowheadPharma

Prossima data di guadagno

2024-11-27

Ultimi documenti SEC

ARWR's Discussions on Twitter

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-04	Iniziato	BofA Securities	Buy
2023-09-19	Iniziato	Citigroup	Neutral
2023-07-21	Iniziato	TD Cowen	Outperform
2023-05-12	Downgrade	SVB Securities	Outperform → Market Perform
2023-04-26	Iniziato	SMBC Nikko	Outperform
2023-04-12	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2022-09-09	Iniziato	Morgan Stanley	Equal-Weight
2022-05-11	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-01-19	Ripresa	Goldman	Buy
2021-08-06	Reiterato	Chardan Capital Markets	Buy
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-02-05	Reiterato	H.C. Wainwright	Buy
2020-12-21	Downgrade	Robert W. Baird	Outperform → Neutral
2020-12-16	Iniziato	UBS	Buy
2020-11-19	Iniziato	Citigroup	Buy
2020-05-13	Iniziato	RBC Capital Mkts	Outperform
2020-05-08	Aggiornamento	Oppenheimer	Perform → Outperform
2020-04-15	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-03-24	Aggiornamento	SVB Leerink	Underperform → Mkt Perform
2020-03-17	Iniziato	Goldman	Neutral
2020-01-21	Iniziato	SVB Leerink	Underperform
2019-12-13	Iniziato	Oppenheimer	Perform
2019-11-29	Reiterato	Chardan Capital Markets	Buy
2019-11-27	Reiterato	B. Riley FBR	Buy
2019-11-25	Aggiornamento	Robert W. Baird	Neutral → Outperform
2019-10-24	Downgrade	Robert W. Baird	Outperform → Neutral
2019-10-22	Reiterato	Chardan Capital Markets	Buy
2019-10-03	Iniziato	Robert W. Baird	Outperform
2018-09-07	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-09-06	Reiterato	Chardan Capital Markets	Buy
2018-08-08	Reiterato	Cantor Fitzgerald	Overweight
2018-07-02	Reiterato	Chardan Capital Markets	Buy

Mostra tutto

Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie

07:31 AM

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - The Bakersfield Californian

07:31 AM

Nov 04, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - BioSpace

Nov 04, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - BioSpace

Nov 04, 2024

Nov 03, 2024

abrdn plc Has $7.77 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Nov 03, 2024

Nov 01, 2024

Arrowhead Launches FCS Awareness Campaign - Baystreet.ca

Nov 01, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, 'We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Quantisnow

Nov 01, 2024

In the wake of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest US$108m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St

Nov 01, 2024

Oct 31, 2024

International Assets Investment Management LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 31, 2024

Oct 30, 2024

(ARWR) Long Term Investment Analysis - Stock Traders Daily

Oct 30, 2024

Assenagon Asset Management S.A. Has $5.68 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 30, 2024

Oct 28, 2024

Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $45.33 - MarketBeat

Oct 28, 2024

Oct 21, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.4%Here's Why - MarketBeat

Oct 21, 2024

Oct 20, 2024

(ARWR) Trading Signals - Stock Traders Daily

Oct 20, 2024

Oct 18, 2024

Buffington Mohr McNeal Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 18, 2024

Oct 17, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - MarketBeat

Oct 17, 2024

Oct 16, 2024

State Street Corp's Strategic Acquisition in Arrowhead Pharmaceu - GuruFocus.com

Oct 16, 2024

Oct 15, 2024

Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma - The Globe and Mail

Oct 15, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)October 14, 2024 - BioSpace

Oct 15, 2024

Oct 11, 2024

HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat

Oct 11, 2024

Arrowhead Pharmaceuticals (STU:HDP1) EV-to-Revenue : 93.89 (As of Oct. 11, 2024) - GuruFocus.com

Oct 11, 2024

Oct 10, 2024

Dimensional Fund Advisors LP Boosts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 10, 2024

Oct 09, 2024